Study | Nation | Â | Study design | Treatment arm | Period | Number of patients | Age (years) | Level of catheter | Medications | HI |
---|---|---|---|---|---|---|---|---|---|---|
Hall 2014 [16] | USA |  | Retrospective case-control study | PVB | 2009/06– 2011/08 | 10 | 15.5 ± 2.3 | T6 TP | 7ml/hr 0.2% R | NR |
 |  |  |  | TEA | 2010/10– 2012/01 | 10 | 14.5 ± 2.5 | T5 | 7ml/hr 0.2% R | NR |
Loftus 2016 [34] | USA |  | Retrospective observation study | PVB | 2009/01– 2012/12 | 28 | NR | NR | NR | NR |
 |  |  |  | TEA |  | 80 | NR | NR | NR | NR |
Beltran 2017 [17] | Canada |  | Retrospective observation study | PVB | 2011– 2013 | 7 | 15.7 ± 1.3 | T45,T56 | 0.25–0.5 mg/kg 0.2% R with PCA | 4.8 ± 1.6 |
 |  |  |  | TEA |  | 8 | 15.8 ± 1.6 | T567 | 0.1% R or 0.125% B with fentanyl 2mcg/ml | 4.5 ± 1.4 |
Muhly 2019 [18] | USA |  | Prospective observation multi-institutional study | PVB | 2014/6– 2015/8 | 56 | 14.9 ± 2.8 | D | D | 4.8 ± 1.6 |
 |  |  |  | TEA |  | 114 | 14.9 ± 2.4 | D | D | 4.5 ± 1.4 |
Bliss 2022 [25] | USA |  | Retrospective observation study | ESP | NR | 30 | 15.4 ± 1.2 | T5–6 | 0.5% R 6ml/hrinitial (0.25 mg/kg/hr max) | 7.3 ± 1.6 |
 |  |  |  | TEA |  | 30 | 14.9 ± 1.3 | NR | 0.2% R with hydromorphine 2–5mcg/ml | 4.2 ± 1.4 |
Santana 2022 [23] | USA |  | Retrospective observation study | ESP | 2014/1– 2020/1 | 19 | 15.6 ± 1.8 | T4–T6 | 0.2% R with 1mcg/ml clonidine | 5.2 ± 1.1 |
 |  |  |  | TEA |  | 41 | 15 ± 2.2 | NA | NR | 5.5 ± 2.2 |
Walter 2023 [24] | USA |  | Retrospective observation study | ESP | 2019/1– 2021/5 | 97 | 15.3 ± 2.3 | T5 TP | 0.125–0.2% R 6–8ml/hr with clonidine 0.5mcg/ml | 4.8 ± 4.6 |
 |  |  |  | TEA |  | 114 | 15 ± 3 | T45T56 | 0.2% R 10–12ml/hr | 4.9 ± 4.6 |